Provigil ( DrugBank: - )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 2 |
| 113 | 筋ジストロフィー | 1 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00220506 (ClinicalTrials.gov) | September 2005 | 14/9/2005 | Fatigue Treatment Using Provigil | Fatigue Treatment Using Provigil in Patients With Relapsing Remitting Multiple Sclerosis | All Multiple Sclerosis Patients | Drug: Provigil | Sheba Medical Center | NULL | Recruiting | 18 Years | 55 Years | Both | 50 | N/A | Israel |
| 2 | NCT00210301 (ClinicalTrials.gov) | January 2003 | 13/9/2005 | Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS | Combination Therapy (Provigil + Avonex) in the Treatment of Attention Problems in Patients With Relapsing-Remitting MS | Relapsing-Remitting Multiple Sclerosis | Drug: Provigil (modafinil) | Institute for Clinical Research | NULL | Recruiting | 20 Years | 65 Years | Both | 60 | N/A | United States |
113. 筋ジストロフィー
臨床試験数 : 622 / 薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-000601-36-IT (EUCTR) | 26/07/2016 | 08/06/2021 | Clinical trial on the efficacy of non invasive ventilation and modafinil on excessive daytime sleepiness in Myotonic Dystrophy type 1 | CLINICAL EFFICACY OF NIV AND MODAFINIL ON EXCESSIVE DAYTIME SLEEPINESS: AMULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL IN DM1 - ModaNIV | Myotonic Dystrophy type 1 MedDRA version: 20.0;Level: PT;Classification code 10068871;Term: Myotonic dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: PROVIGIL - 100 MG COMPRESSE 30 COMPRESSE | FONDAZIONE SERENA ONLUS | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 3 | Italy |